Depressive DisordersSubstance Use Disorders (SUD)Health Economics & Reimbursement

Psychedelic-assisted psychotherapy: Where is the psychotherapy research?

This review (2024) scrutinizes the role of psychotherapy in psychedelic-assisted psychotherapy (PAP/PAT) for mental health conditions. It underscores a significant research gap in understanding the psychotherapeutic elements within PAT, despite its assumed importance for safety and efficacy. The paper calls for a transdisciplinary approach in future research to optimize PAT clinical outcomes and inform federal guidelines.

Authors

  • Joshua Woolley
  • Jordan Aday
  • Ellen Bradley

Published

Psychopharmacology
meta Study

Abstract

Rationale

Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models of PAP emphasize the importance of psychotherapeutic support before, during, and after ingestion of a psychedelic to maximize safety and clinical benefit. Despite this ubiquitous assumption, there has been surprisingly little empirical investigation of the “psychotherapy” in PAP, leaving critical questions about the necessary and sufficient components of PAP unanswered.

Objectives

As clinical trials for psychedelic compounds continue the transition from safety- and feasibility-testing to evaluating efficacy, the role of the accompanying psychotherapy must be better understood to enhance scientific understanding of the mechanisms underlying therapeutic change, optimize clinical outcomes, and inform cost-effectiveness.

Results

The present paper first reviews the current status of psychotherapy in the PAP literature, starting with recent debates regarding “psychotherapy” versus “psychological support” and then overviewing published clinical trial psychotherapy models and putative models informed by theory. We then delineate lessons that PAP researchers can leverage from traditional psychotherapy research regarding standardizing treatments (e.g., publish treatment manuals, establish eligibility criteria for providers), identifying mechanisms of change (e.g., measure established mechanisms in psychotherapy), and optimizing clinical trial designs (e.g., consider dismantling studies, comparative efficacy trials, and cross-lagged panel designs). Throughout this review, the need for increased research into the psychotherapeutic components of treatment in PAP is underscored.

Conclusions

PAP is a distinct, integrative, and transdisciplinary intervention. Future research designs should consider transdisciplinary research methodologies to identify best practices and inform federal guidelines for PAP administration.

Available with Blossom Pro

Research Summary of 'Psychedelic-assisted psychotherapy: Where is the psychotherapy research?'

Introduction

High-dose administration of classic psychedelics paired with psychotherapeutic support before, during, and after dosing sessions is increasingly being studied as a potential treatment for several psychiatric conditions. Aday and colleagues describe two principal rationales for combining drug and psychotherapy: safety (therapeutic support is thought to reduce the acute risks of giving a psychedelic) and efficacy (psychedelics may transiently relax prior beliefs, increase suggestibility, and promote neuroplasticity in ways that could augment psychotherapeutic processes). The authors emphasise that this context sensitivity makes it important to understand which psychotherapeutic elements are necessary or sufficient for clinical benefit. The paper sets out to review the current status of psychotherapy within psychedelic-assisted psychotherapy (PAP), summarising psychotherapeutic models used in published clinical trials and putative models proposed in the literature. It also aims to draw lessons from decades of traditional psychotherapy research about standardising treatments, identifying mechanisms of change, and optimising trial design, with the overarching goal of highlighting gaps and priorities for empirical study of the psychotherapeutic component of PAP.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (40)

Papers cited by this study that are also in Blossom

Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials

Aday, J. S., Heifets, B. D., Pratscher, S. D. et al. · Psychopharmacology (2021)

Psychedelics and virtual reality: parallels and applications

Aday, J. S., Davoli, C. C., Bloesch, E. K. · Therapeutic Advances in Psychopharmacology (2020)

Effects of psilocybin versus escitalopram on rumination and thought suppression in depression

Barba, T., Buehler, S., Kettner, H. et al. · BJPsych Open (2022)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)

Show all 40 references
LSD enhances suggestibility in healthy volunteers

Carhart-Harris, R. L., Kaelen, M., Whalley, M. G. et al. · Psychopharmacology (2014)

257 cited
Psychedelic-Assisted Psychotherapy-A Systematic Review of Associated Psychological Interventions

Cavarra, M., Falzone, A., Ramaekers, J. G. et al. · Frontiers in Psychology (2022)

Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD

Davis, A. K., Streeter Barrett, F., Griffiths, R. R. et al. · Journal of Psychopharmacology (2021)

108 cited
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder

Doss, M. K., Považan, M., Rosenberg, M. D. et al. · Translational Psychiatry (2021)

249 cited
Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature

Golden, T. L., Magsamen, S., Sandu, C. C. et al. · Current Topics in Behavioral Neurosciences (2022)

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)

656 cited
Must Psilocybin Always “Assist Psychotherapy”?

Goodwin, G. M., Malievskaia, E., Fonzo, G. A. et al. · American Journal of Psychiatry (2023)

143 cited
Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy

Horton, D. M., Morrison, B., Schmidt, J. · American Journal of Psychotherapy (2021)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression

Murphy, R., Murphy-Beiner, A., Kettner, H. et al. · Frontiers in Pharmacology (2022)

162 cited
Psychedelics reopen the social reward learning critical period

Nardou, R., Sawyer, E., Song, Y. J. et al. · Nature (2023)

Lower-dose psycholytic therapy - A neglected approach

Passie, T., Guss, J., Kraehenmann, R. · Frontiers in Psychiatry (2022)

Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience

Peill, J. M., Trinci, K. E., Kettner, H. et al. · Journal of Psychopharmacology (2022)

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science

Neil, J. C., Nutt, D. J. · Journal of Psychopharmacology (2022)

Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame

Sloshower, J., Guss, J., Krause, R. et al. · Journal of Contextual Behavioral Science (2020)

Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy

Strickland, J. C., Garcia-Romeu, A., Johnson, M. W. · ACS Pharmacology and Translational Science (2020)

Psychedelic-Assisted Group Therapy: A Systematic Review

Trope, A., Anderson, B. T., Hooker, A. R. et al. · Journal of Psychoactive Drugs (2019)

The use of the psychological flexibility model to support psychedelic assisted therapy

Watts, R., Luoma, J. B. · Journal of Contextual Behavioral Science (2020)

Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance

Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)

82 cited

Cited By (4)

Papers in Blossom that reference this study

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Psychedelic-assisted psychotherapy: Where is the... — Research Summary & Context | Blossom